SCHEMBL4489826

SCHEMBL4489826

CSc1cc2c(c(C(C)(C)CC3(C(F)(F)F)COC(C)(C)O3)c1)OCC2

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 3/20 0.30
PGR P06401 3/20 0.30
NR3C2 P08235 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4167063 0.89 NR3C1 (0.33) NR3C1PGRNR3C2
SCHEMBL4490217 0.85 NR3C1 (0.42) NR3C1PGRNR3C2
SCHEMBL13754638 0.84 NR3C1 (0.31) NR3C1PGRNR3C2
SCHEMBL15756223 0.81 NR3C1 (0.37) NR3C1PGRNR3C2
SCHEMBL5798659 0.81 NR3C1 (0.37) NR3C1PGRNR3C2
SCHEMBL12534236 0.74 NR3C1 (0.45) NR3C1PGRNR3C2
SCHEMBL5355509 0.74 NR3C1 (0.43) NR3C1PGRNR3C2
SCHEMBL5363258 0.74 NR3C1 (0.46) NR3C1PGRNR3C2
SCHEMBL5355518 0.74 NR3C1 (0.43) NR3C1PGRNR3C2
SCHEMBL5363254 0.74 NR3C1 (0.46) NR3C1PGRNR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579469-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-08-25 US disclosed
EP-1583745-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-10-12 EP disclosed
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-08-19 US disclosed
WO-2004063163-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof NR3C1, NR3C2, MC2R NR3C1 1/4885PGR 198/4885NR3C2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.